Adiso Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $70M

  • Investors
  • 2

Adiso Therapeutics General Information

Description

Developer of novel therapeutics designed to treat inflammatory diseases with improved safety and efficacy. The company platform offers a pipeline of multi-modal agents, including gut-restricted neutrophil modulators and inflammasome inhibitors, enabling patients with ulcerative colitis, respiratory conditions, and neuroinflammatory diseases to achieve better treatment outcomes.

Contact Information

Website
www.adisotx.com
Formerly Known As
Artugen Therapeutics, Bacainn Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1188 Centre Street
  • Newton Centre
  • Newton, MA 02459
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1188 Centre Street
  • Newton Centre
  • Newton, MA 02459
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adiso Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 01-Jan-2022 $70M Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 10-Mar-2022 Completed Clinical Trials - Phase 2
1. Merger of Equals 10-Mar-2022 Completed Clinical Trials - Phase 2
To view Adiso Therapeutics’s complete valuation and funding history, request access »

Adiso Therapeutics Patents

Adiso Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025085674-A1 Methods and compositions for the treatment of ulcerative colitis Inactive 20-Oct-2023
EP-4680258-A1 Bacillus amyloliquefaciens strains art12 and art24 for the treatment of disorders of the cns Pending 17-Mar-2023
WO-2024194737-A1 Bacillus amyloliquefaciens strains art12 and art24 for the treatment of disorders of the cns Inactive 17-Mar-2023
WO-2024097229-A1 Probenecid compounds for the treatment of inflammasome-mediated dermatological conditions Inactive 04-Nov-2022
WO-2024047527-A1 Methods and compositions for preventing and treating chemotherapy-induced peripheral neuropathy Inactive 01-Sep-2022 A61K35/742
To view Adiso Therapeutics’s complete patent history, request access »

Adiso Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adiso Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bacainn Therapeutics Corporation Majority
Morningside Group Venture Capital Majority
To view Adiso Therapeutics’s complete investors history, request access »

Adiso Therapeutics Acquisitions (2)

Adiso Therapeutics’s most recent deal was a Merger/Acquisition with Artugen Therapeutics. The deal was made on 10-Mar-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Artugen Therapeutics 10-Mar-2022 Merger/Acquisition Drug Discovery
Bacainn Therapeutics 10-Mar-2022 Merger/Acquisition Drug Discovery
To view Adiso Therapeutics’s complete acquisitions history, request access »

Adiso Therapeutics FAQs

  • When was Adiso Therapeutics founded?

    Adiso Therapeutics was founded in 2022.

  • Where is Adiso Therapeutics headquartered?

    Adiso Therapeutics is headquartered in Newton, MA.

  • What is the size of Adiso Therapeutics?

    Adiso Therapeutics has 18 total employees.

  • What industry is Adiso Therapeutics in?

    Adiso Therapeutics’s primary industry is Drug Discovery.

  • Is Adiso Therapeutics a private or public company?

    Adiso Therapeutics is a Private company.

  • What is Adiso Therapeutics’s current revenue?

    The current revenue for Adiso Therapeutics is .

  • How much funding has Adiso Therapeutics raised over time?

    Adiso Therapeutics has raised $130M.

  • Who are Adiso Therapeutics’s investors?

    Bacainn Therapeutics and Morningside Group have invested in Adiso Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process